Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion. 2001

M Beghetti, and M Berner, and P C Rimensberger
Cardiology Unit, Hôpital des Enfants, Department of Paediatrics, University Hospital of Geneva, 1211 Genève 14, Switzerland. maurice.beghetti@hcuge.ch

Primary pulmonary hypertension is a rare disease in childhood associated with a poor prognosis. However, during the past 10 years, pulmonary vasodilator treatment has somewhat improved its prognosis. Long term continuous infusion of prostacyclin (epoprostenol) has been shown to improve physical capacity and to reduce mortality in primary and secondary pulmonary hypertension. It has been reported in adults that daily repetitive inhalation of iloprost, a prostacyclin analogue, seems also suitable for long term therapy of pulmonary hypertension. Repetitive inhalation of iloprost was administered to a 5 year old boy with severe primary pulmonary hypertension. He showed continuous clinical improvement without any side effects over the three years of treatment. This treatment may offer an alternative to continuous intravenous prostacyclin infusion and obviates the need for a permanent central venous catheter.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D008297 Male Males
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D016285 Iloprost An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation. Ciloprost,Ventavis,ZK-36374,ZK 36374,ZK36374

Related Publications

M Beghetti, and M Berner, and P C Rimensberger
January 2001, Pneumologie (Stuttgart, Germany),
M Beghetti, and M Berner, and P C Rimensberger
November 1997, Internal medicine (Tokyo, Japan),
M Beghetti, and M Berner, and P C Rimensberger
June 2000, The New England journal of medicine,
M Beghetti, and M Berner, and P C Rimensberger
August 1997, Journal of the American College of Cardiology,
M Beghetti, and M Berner, and P C Rimensberger
February 1998, Heart (British Cardiac Society),
M Beghetti, and M Berner, and P C Rimensberger
June 2001, The European respiratory journal,
M Beghetti, and M Berner, and P C Rimensberger
July 2001, The European respiratory journal,
M Beghetti, and M Berner, and P C Rimensberger
January 2001, The European respiratory journal,
M Beghetti, and M Berner, and P C Rimensberger
October 1994, Arthritis and rheumatism,
M Beghetti, and M Berner, and P C Rimensberger
February 2003, Zhonghua nei ke za zhi,
Copied contents to your clipboard!